Non Alcoholic Fatty Liver Disease Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
BLTE | C | Belite Bio, Inc. | 0.55 | |
TERN | C | Terns Pharmaceuticals, Inc. | 2.08 | |
AKRO | D | Akero Therapeutics, Inc. | -2.01 | |
GNFT | D | GENFIT S.A. | 0.00 | |
VKTX | D | Viking Therapeutics, Inc. | -2.08 | |
IVA | D | Inventiva S.A. | 4.21 | |
GYRE | F | Gyre Therapeutics, Inc. | -2.98 | |
ALGS | F | Aligos Therapeutics, Inc. | 5.63 | |
GALT | F | Galectin Therapeutics Inc. | -5.70 | |
GLTO | F | Galecto, Inc. | 9.95 |
Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Health Information Services
Related Stock Lists:
Steatohepatitis
Hepatitis
Alcohol
Liver Disease
Biopharmaceutical
Medicine
Cancer
Clinical Medicine
Fibrosis
Biology
Biotechnology
Breakthrough Therapy
Chronic Liver Diseases
Diabetes
Drug Development
Fibrotic Disease
Galectin
Galectin 3
Galecto Biotech
Idiopathic Pulmonary Fibrosis
Related ETFs - A few ETFs which own one or more of the above listed Non Alcoholic Fatty Liver Disease stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
OZEM | D | Roundhill GLP-1 & Weight Loss ETF | 6.59 | |
ULTY | B | Tidal Trust II YieldMax Ultra Option Income Strategy ETF | 5.16 | |
SURI | C | Simplify Exchange Traded Funds Simplify Propel Opportunities ETF | 4.39 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 3.38 | |
XBI | C | SPDR S&P Biotech ETF | 2.73 |
Compare ETFs
Related Industries:
Biotechnology
Drug Manufacturers - Specialty & Generic
Health Information Services
Related Stock Lists:
Steatohepatitis
Hepatitis
Alcohol
Liver Disease
Biopharmaceutical
Medicine
Cancer
Clinical Medicine
Fibrosis
Biology
Biotechnology
Breakthrough Therapy
Chronic Liver Diseases
Diabetes
Drug Development
Fibrotic Disease
Galectin
Galectin 3
Galecto Biotech
Idiopathic Pulmonary Fibrosis
- Non Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles